Jnana Therapeutics today announced that UC Berkeley Chemistry alum Joanne Kotz, Ph.D., a company co-founder, has been named Chief Executive Officer. Dr. Kotz has served as Jnana's president since December 2017.
A statement about the U.S. Court of Appeals decision on the University of California's patent interference claim before the Patent Trial and Appeal Board b by Charles F. Robinson, Office of General Counsel, UC Office of the President.
The Court of Appeals today concluded that the use of CRISPR-Cas9 in plant and animal cells is separately patentable from Drs. Doudna and Charpentier's invention of the use of CRISPR-Cas9 in any environment. We are evaluating further litigation options. We also look forward to proving that Drs. Doudna and Charpentier first invented usage in plant and animal cells – a fact that is already widely recognized by the global scientific community – as the Doudna-Charpentier team's several pending patent applications that cover use of CRISPR-Cas9 in plant and animal cells are now under examination by the patent office.
John Casida, one of the world's leading authorities on how pesticides work and how they can potentially harm humans. Casida was the founding director of the campus's Environmental Chemistry and Toxicology Laboratory.